Chemotherapy-related polyneuropathy may deteriorate quality of life in patients with B-cell lymphoma

Byung Jo Kim, Ha Rim Park, Hak Jae Roh, Du Shin Jeong, Byung Soo Kim, Kun Woo Park, S. Charles Cho, Yuen T. So, Sung Yong Oh, Seok Jin Kim

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Purpose This prospective study was performed to evaluate the effect of chemotherapy-related neurotoxicity on quality of life (QOL) of patients with lymphoma. Methods Thirty-two patients with diffuse large B-cell or follicular lymphoma without prior evidence of neuropathy were enrolled. Patients underwent the evaluations based on neuropathy symptom and disability score, nerve conduction studies, and SF-36 questionnaire for QOL assessment. They received six cycles of chemotherapy every three weeks, and all evaluations were repeated during and after the completion of 6th cycle. Results Sensory neuropathy-associated symptoms were observed in 27 patients (84.4%), and polyneuropathy was confirmed by nerve conduction study in 14 patients (43.8%). These patients with polyneuropathy showed worse QOL in domains mainly associated with physical health status including "physical function" compared to patients without polyneuropathy. There was a significant association of neuropathy symptom and disability scores with "bodily pain" and "vitality" of QOL domains. The serial evaluations of patients with neuropathy showed a worsening of QOL and neuropathy symptom scores during chemotherapy, then improvement of these values after chemotherapy. Thus, the final nerve conduction study confirmed the decrease in polyneuropathy compared to the 2nd evaluation (P = 0.032). Conclusion Chemotherapy-related polyneuropathy may deteriorate QOL of patients with lymphoma, mainly physical health-associated QOL.

Original languageEnglish
Pages (from-to)1097-1103
Number of pages7
JournalQuality of Life Research
Volume19
Issue number8
DOIs
Publication statusPublished - 2010 Oct 1

Fingerprint

Polyneuropathies
B-Cell Lymphoma
Quality of Life
Drug Therapy
Neural Conduction
Lymphoma
Follicular Lymphoma
Lymphoma, Large B-Cell, Diffuse
Health Status
Prospective Studies
Pain
Health

Keywords

  • Chemotherapy
  • Lymphoma
  • Neuropathy
  • Quality of life

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • Medicine(all)

Cite this

Chemotherapy-related polyneuropathy may deteriorate quality of life in patients with B-cell lymphoma. / Kim, Byung Jo; Park, Ha Rim; Roh, Hak Jae; Jeong, Du Shin; Kim, Byung Soo; Park, Kun Woo; Cho, S. Charles; So, Yuen T.; Oh, Sung Yong; Kim, Seok Jin.

In: Quality of Life Research, Vol. 19, No. 8, 01.10.2010, p. 1097-1103.

Research output: Contribution to journalArticle

Kim, Byung Jo ; Park, Ha Rim ; Roh, Hak Jae ; Jeong, Du Shin ; Kim, Byung Soo ; Park, Kun Woo ; Cho, S. Charles ; So, Yuen T. ; Oh, Sung Yong ; Kim, Seok Jin. / Chemotherapy-related polyneuropathy may deteriorate quality of life in patients with B-cell lymphoma. In: Quality of Life Research. 2010 ; Vol. 19, No. 8. pp. 1097-1103.
@article{9f3a6d97bfdf4a53801c8068e7648601,
title = "Chemotherapy-related polyneuropathy may deteriorate quality of life in patients with B-cell lymphoma",
abstract = "Purpose This prospective study was performed to evaluate the effect of chemotherapy-related neurotoxicity on quality of life (QOL) of patients with lymphoma. Methods Thirty-two patients with diffuse large B-cell or follicular lymphoma without prior evidence of neuropathy were enrolled. Patients underwent the evaluations based on neuropathy symptom and disability score, nerve conduction studies, and SF-36 questionnaire for QOL assessment. They received six cycles of chemotherapy every three weeks, and all evaluations were repeated during and after the completion of 6th cycle. Results Sensory neuropathy-associated symptoms were observed in 27 patients (84.4{\%}), and polyneuropathy was confirmed by nerve conduction study in 14 patients (43.8{\%}). These patients with polyneuropathy showed worse QOL in domains mainly associated with physical health status including {"}physical function{"} compared to patients without polyneuropathy. There was a significant association of neuropathy symptom and disability scores with {"}bodily pain{"} and {"}vitality{"} of QOL domains. The serial evaluations of patients with neuropathy showed a worsening of QOL and neuropathy symptom scores during chemotherapy, then improvement of these values after chemotherapy. Thus, the final nerve conduction study confirmed the decrease in polyneuropathy compared to the 2nd evaluation (P = 0.032). Conclusion Chemotherapy-related polyneuropathy may deteriorate QOL of patients with lymphoma, mainly physical health-associated QOL.",
keywords = "Chemotherapy, Lymphoma, Neuropathy, Quality of life",
author = "Kim, {Byung Jo} and Park, {Ha Rim} and Roh, {Hak Jae} and Jeong, {Du Shin} and Kim, {Byung Soo} and Park, {Kun Woo} and Cho, {S. Charles} and So, {Yuen T.} and Oh, {Sung Yong} and Kim, {Seok Jin}",
year = "2010",
month = "10",
day = "1",
doi = "10.1007/s11136-010-9670-0",
language = "English",
volume = "19",
pages = "1097--1103",
journal = "Quality of Life Research",
issn = "0962-9343",
publisher = "Springer Netherlands",
number = "8",

}

TY - JOUR

T1 - Chemotherapy-related polyneuropathy may deteriorate quality of life in patients with B-cell lymphoma

AU - Kim, Byung Jo

AU - Park, Ha Rim

AU - Roh, Hak Jae

AU - Jeong, Du Shin

AU - Kim, Byung Soo

AU - Park, Kun Woo

AU - Cho, S. Charles

AU - So, Yuen T.

AU - Oh, Sung Yong

AU - Kim, Seok Jin

PY - 2010/10/1

Y1 - 2010/10/1

N2 - Purpose This prospective study was performed to evaluate the effect of chemotherapy-related neurotoxicity on quality of life (QOL) of patients with lymphoma. Methods Thirty-two patients with diffuse large B-cell or follicular lymphoma without prior evidence of neuropathy were enrolled. Patients underwent the evaluations based on neuropathy symptom and disability score, nerve conduction studies, and SF-36 questionnaire for QOL assessment. They received six cycles of chemotherapy every three weeks, and all evaluations were repeated during and after the completion of 6th cycle. Results Sensory neuropathy-associated symptoms were observed in 27 patients (84.4%), and polyneuropathy was confirmed by nerve conduction study in 14 patients (43.8%). These patients with polyneuropathy showed worse QOL in domains mainly associated with physical health status including "physical function" compared to patients without polyneuropathy. There was a significant association of neuropathy symptom and disability scores with "bodily pain" and "vitality" of QOL domains. The serial evaluations of patients with neuropathy showed a worsening of QOL and neuropathy symptom scores during chemotherapy, then improvement of these values after chemotherapy. Thus, the final nerve conduction study confirmed the decrease in polyneuropathy compared to the 2nd evaluation (P = 0.032). Conclusion Chemotherapy-related polyneuropathy may deteriorate QOL of patients with lymphoma, mainly physical health-associated QOL.

AB - Purpose This prospective study was performed to evaluate the effect of chemotherapy-related neurotoxicity on quality of life (QOL) of patients with lymphoma. Methods Thirty-two patients with diffuse large B-cell or follicular lymphoma without prior evidence of neuropathy were enrolled. Patients underwent the evaluations based on neuropathy symptom and disability score, nerve conduction studies, and SF-36 questionnaire for QOL assessment. They received six cycles of chemotherapy every three weeks, and all evaluations were repeated during and after the completion of 6th cycle. Results Sensory neuropathy-associated symptoms were observed in 27 patients (84.4%), and polyneuropathy was confirmed by nerve conduction study in 14 patients (43.8%). These patients with polyneuropathy showed worse QOL in domains mainly associated with physical health status including "physical function" compared to patients without polyneuropathy. There was a significant association of neuropathy symptom and disability scores with "bodily pain" and "vitality" of QOL domains. The serial evaluations of patients with neuropathy showed a worsening of QOL and neuropathy symptom scores during chemotherapy, then improvement of these values after chemotherapy. Thus, the final nerve conduction study confirmed the decrease in polyneuropathy compared to the 2nd evaluation (P = 0.032). Conclusion Chemotherapy-related polyneuropathy may deteriorate QOL of patients with lymphoma, mainly physical health-associated QOL.

KW - Chemotherapy

KW - Lymphoma

KW - Neuropathy

KW - Quality of life

UR - http://www.scopus.com/inward/record.url?scp=79951919708&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79951919708&partnerID=8YFLogxK

U2 - 10.1007/s11136-010-9670-0

DO - 10.1007/s11136-010-9670-0

M3 - Article

VL - 19

SP - 1097

EP - 1103

JO - Quality of Life Research

JF - Quality of Life Research

SN - 0962-9343

IS - 8

ER -